CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T
/ SZGIMI
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
June 24, 2026
Universal CAR-T Cells Targeting AML
(clinicaltrials.gov)
- P1 | N=30 | Recruiting | Sponsor: Shenzhen Geno-Immune Medical Institute | Trial completion date: Dec 2026 ➔ Dec 2030 | Trial primary completion date: Sep 2026 ➔ Dec 2029
Trial completion date • Trial primary completion date • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • CD33 • CD38 • IL3RA
August 16, 2023
Universal CAR-T Cells Targeting AML
(clinicaltrials.gov)
- P1 | N=30 | Recruiting | Sponsor: Shenzhen Geno-Immune Medical Institute
CAR T-Cell Therapy • New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • CD33 • CD38 • IL3RA
1 to 2
Of
2
Go to page
1